Stock NVCR NOVOCURE LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Real-time Estimate Cboe BZX
Other stock markets
 15:11:56 2024-06-26 EDT 		5-day change 1st Jan Change
18.2 USD +0.91% Intraday chart for NovoCure Limited -4.93% +22.10%
06-04 Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating MT
06-03 Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
BU
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
BU
NovoCure: Q1 Earnings Snapshot
AQ
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
BU
Novocure Reports First Quarter 2024 Financial Results
BU
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
BU
NovoCure : Corporate responsibility report
PU
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research Annual Meeting 2024
AQ
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
BU
Novocure to Report First Quarter 2024 Financial Results
BU
Novocure - METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
AQ
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases
AQ
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
BU
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
BU
NovoCure: Q4 Earnings Snapshot
AQ
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
BU
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
BU
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
BU
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
BU
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NVCR Stock
  4. News NovoCure Limited
  5. Press Releases